SEMA7A, His, Human
| $340.00 | |
| Z05803-100 | |
|
|
|
|
|
|
|
|
|
| Ask us a question | |
IVD Raw Materials
| $340.00 | |
| Z05803-100 | |
|
|
|
|
|
|
|
|
|
| Ask us a question | |
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity | > 95% as determined by Bis-Tris PAGE | ||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 69.5 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 70-75 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. |
SEMA7A, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | Semaphorin7A (Sema7A) plays an important role in the immunoregulation of the brain.Sema7A is upregulated in the epileptic brain and plays a potential role in the regulation of seizure activity in PTZ-kindled epileptic rats, which may be related to neuroinflammation. Sema7A promotes the inflammatory cytokines TNF-α and IL-6 as well as the growth of mossy fibers through the ERK pathway, suggesting that Sema7A may promote seizures by increasing neuroinflammation and activating pathological neural circuits. Sema7A plays a critical role in epilepsy and could be a potential therapeutic target for this neurological disorder. |
| Synonyms | Semaphorin-7A; Semaphorin-K1; Semaphorin-L; Sema L; CD108; CD108MGC126696; CDw108; H-SEMA-K1; H-Sema-L; JMH; MGC126692; Sema7A; SEMAK1; SEMAL |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.